EN
登录

AGC Biologics与 Child’s Cure Genetic Research合作,开发用于严重癫痫疾病的 mRNA疗法

AGC Biologics partners with Child’s Cure Genetic Research to pursue mRNA-based therapeutic for severe epileptic disorder

GlobeNewswire 等信源发布 2026-11-10 14:00

可切换为仅中文


Demonstrates new evolution in mRNA to address rare conditions

展示mRNA技术在应对罕见病方面的新进展

CDMO’s work with parent-led, patient-focused foundation will investigate a development pathway to combat CDKL5 Deficiency Disorder

CDMO 将与一家由家长主导、以患者为中心的基金会合作,探索对抗 CDKL5 缺乏症的开发路径

AGC Biologics is well positioned to help advance mRNA programs toward the clinic

AGC Biologics 具备有利优势,能够推动 mRNA 项目向临床应用迈进

HEIDELBERG, Germany, Nov. 10, 2026 (GLOBE NEWSWIRE) -- In a world where patients with CDKL5 deficiencies can suffer 40 to 60 epileptic seizures a day, a contract biopharmaceutical manufacturer and a parent-founded foundation will partner on early-stage messenger RNA development to find a long-term treatment for the rare neurodevelopmental disease.

德国海德堡,2026年11月10日(环球电讯社)——在CDKL5缺乏症患者每天可能遭受40至60次癫痫发作的世界里,一家合同生物制药制造商与一家由家长创立的基金会将合作开展早期信使RNA(mRNA)研发,以寻求针对这种罕见神经发育疾病的长期治疗方案。

.

。

With few RNA-based programs in development for rare diseases,

由于针对罕见病的基于RNA的研发项目寥寥无几,

Child’s Cure Genetic Research

儿童治愈遗传学研究

and

和

AGC Biologics

AGC生物制剂

will collaborate to identify a viable path for a new mRNA therapeutic that mimics the protein made by the CDKL5 gene. The intent of the protein-sustaining treatment is to reduce seizures, improve neurological development, and help patients—many of whom are babies and young children—gain control from debilitating symptoms that impede their health and potential..

将开展合作,为一种模拟CDKL5基因所产生蛋白质的新型mRNA疗法确定可行路径。该蛋白质维持疗法旨在减少癫痫发作,促进神经发育,并帮助患者(其中许多为婴儿和幼儿)控制那些损害其健康与潜能的致残性症状。

This early proof-of-concept work within

这项早期的概念验证工作

AGC Biologics’ integrated mRNA solutions

AGC Biologics 的一体化 mRNA 解决方案

will seek to identify the best pathway toward clinical development.

将致力于确定通往临床开发的最佳路径。

New rare disease frontier for mRNA

mRNA在罕见病领域的新前沿

Cyclin-dependent kinase-like 5 deficiency disorder is a rare genetic disease caused by mutations or deletions of the CDKL5 gene. Current treatment for the disorder often only consists of supportive care, though the foundation is also exploring a small molecule drug that is presently in clinical trials..

CDKL5缺乏症是一种由CDKL5基因突变或缺失引起的罕见遗传性疾病。目前,该病的治疗通常仅限于支持性护理,尽管相关基金会也在探索一种正处于临床试验阶段的小分子药物。

For young patients like Reyna Jogani, advancement is not happening at the speed she needs to get the critical CDKL5 protein that enables routine brain activity related to movement, learning, vision, and behavior. Reyna’s father, and Child’s Cure co-founder, Jainu Jogani, has embraced the rapid advancement and potential of mRNA development, and this partnership with AGC Biologics aims to uncover a sustaining treatment for the rare disease..

对于像雷娜·乔加尼这样的年轻患者来说,医学进展的速度尚未达到让她及时获得关键的CDKL5蛋白所需的水平,而该蛋白对维持与运动、学习、视觉和行为相关的日常大脑活动至关重要。雷娜的父亲、Child’s Cure联合创始人贾伊努·乔加尼积极拥抱mRNA技术的快速发展及其潜力,此次与AGC Biologics的合作旨在为这种罕见疾病开发一种可持续的治疗方案。

RNA-based therapeutic programs are also in development for rare neurodevelopmental diseases such as Rett and Angelman syndromes. Child’s Cure is pursuing mRNA for CDKL5 deficiency disorder as part of an effort to help advance the application of this approach to rare diseases.

针对雷特综合征和安格曼综合征等罕见神经发育疾病的RNA疗法也在开发中。Child’s Cure公司正在推进用于CDKL5缺乏症疾病的mRNA疗法,作为推动该方法在罕见病领域应用的努力之一。

mRNA therapy will complement gene therapy

mRNA疗法将补充基因疗法

Through this program, Child’s Cure will explore mRNA as a potential complement to a one-time adeno-associated virus gene therapy intended to address the mutated or deleted CDKL5 gene. The mRNA therapy development will explore how to provide ongoing protein replacement infusions and could offer another option for patients with differing needs, including those for whom gene therapy may not be suitable..

通过该项目,Child’s Cure 将探索 mRNA 作为一次性腺相关病毒基因疗法的潜在补充手段,该基因疗法旨在治疗由 CDKL5 基因突变或缺失引起的疾病。mRNA 疗法的开发将研究如何提供持续的蛋白质替代输注,并可能为具有不同需求的患者(包括那些不适合接受基因疗法的患者)提供另一种选择。

'What I’ve learned about CDKL5 deficiency disorder is that one treatment approach may not meet every patient’s needs. Gene therapy may not be an option for every patient, and questions remain about how long a one-time treatment effect will last,” said Jogani. “Investing further in a complementary approach through mRNA intends to restore the missing CDKL5 protein by offering a redosable, adjustable way to support ongoing protein replacement.

“我对CDKL5缺乏症的了解是,一种治疗方法可能无法满足每位患者的需求。基因疗法并非适用于所有患者,而且一次性治疗的效果能持续多久仍存疑问,”Jogani表示。“通过mRNA技术进一步投资一种互补方法,旨在以可重复给药、可调整的方式支持持续的蛋白替代,从而恢复缺失的CDKL5蛋白。”

We are leaving no stone unturned to explore what might help.”.

“我们正竭尽全力探索一切可能有所帮助的途径。”

AGC Biologics’ support for early-phase mRNA programs

AGC Biologics 对早期阶段 mRNA 项目的支持

In 2023, AGC Biologics leveraged 40 years of experience in microbial fermentation as well as expanded plasmid DNA capabilities to create its new messenger RNA service line at its Heidelberg, Germany site. The mRNA process development services provide custom approaches to meet each specific mRNA need and can produce mRNA supply from R&D to GMP grades..

2023年,AGC Biologics凭借其在微生物发酵领域40年的经验以及扩展的质粒DNA能力,在其位于德国海德堡的基地推出了全新的信使RNA(mRNA)服务线。该mRNA工艺开发服务提供定制化方案,以满足各类特定的mRNA需求,并能够生产从研发级到药品生产质量管理规范(GMP)级的mRNA产品。

“Similar to what we’ve established across decades in other modalities, we are invested in delivering early-stage clinical expertise to developers with mRNA candidates looking to translate their discovery into commercial success,” said Christoph Winterhalter, Chief Business Officer of AGC Biologics. “This is an inflection point for this market, where it is progressing into new arenas including personalized medicines and gene therapy.

“与我们在其他领域数十年来所建立的体系类似,我们致力于向拥有mRNA候选产品的开发者提供早期临床专业知识,帮助他们将科研成果转化为商业成功。”AGC Biologics首席商务官Christoph Winterhalter表示。“这是该市场的一个转折点,它正逐步进入包括个性化药物和基因疗法在内的新领域。

Our experts are the best in the marketplace to support this growth and expansion.”.

我们的专家是市场上支持这一增长和扩张的最佳人选。

In November 2025, AGC Biologics announced it would

2025年11月,AGC Biologics宣布将

partner with Repair Biotechnologies

与 Repair Biotechnologies 合作

to develop and manufacture a novel mRNA therapy designed to combat the build-up of atherosclerotic plaques, a major contributor to cardiovascular disease, the leading cause of human mortality.

开发并制造一种新型mRNA疗法,旨在对抗动脉粥样硬化斑块的积聚,而动脉粥样硬化斑块是导致心血管疾病(人类死亡的主要原因)的重要因素。

In 2027, AGC Biologics will also offer mRNA process development and commercial production at its

2027年,AGC Biologics还将在其位于

newest location in Yokohama, Japan

日本横滨最新地点

.

。

Frequently Asked Questions (FAQs):

常见问题解答(FAQ):

Why is Child’s Cure exploring mRNA alongside gene therapy for CDKL5 deficiency disorder?

为什么 Child’s Cure 在研究 CDKL5 缺乏症时,同时探索 mRNA 技术与基因疗法?

The approaches are intended to serve different roles. The AAV gene therapy is intended to address the mutated or deleted CDKL5 gene, while the mRNA program is intended to provide the CDKL5 protein that patients are missing. Child’s Cure is exploring mRNA as a potential complementary or alternative approach because gene therapy may not be suitable for every patient, and the long-term durability of a one-time gene therapy remains an important question.

这些方法旨在发挥不同的作用。AAV基因疗法旨在解决CDKL5基因突变或缺失的问题,而mRNA项目旨在提供患者体内缺失的CDKL5蛋白。Child’s Cure正在探索mRNA作为一种潜在的互补或替代方案,因为基因疗法可能并不适用于每一位患者,且一次性基因疗法的长期持久性仍然是一个重要的问题。

Repeatable mRNA dosing to restore CDKL5 protein production could provide another way to support patients over time, subject to further development and clinical evidence..

通过可重复的mRNA给药来恢复CDKL5蛋白的产生,有望为长期支持患者提供另一种途径,但这有待进一步的开发和临床证据支持。

What experience does AGC Biologics have in working with rare disease therapeutics?

AGC Biologics 在罕见病治疗药物领域拥有哪些合作经验?

Amidst a complicated landscape for rare conditions with small patient populations, therapy development demands innovation and new ways of thinking. Organizations tackling some of the rarest of diseases are choosing AGC Biologics because of its ability to support unconventional development models:

在患者群体较小的罕见病领域,面对错综复杂的局面,疗法开发亟需创新与全新的思维方式。一些致力于攻克最罕见疾病的组织选择与AGC Biologics合作,正是看重其支持非传统开发模式的能力:

AGC Biologics is a

AGC Biologics 是一家

part of the Orphan Therapeutics Accelerator

孤儿药治疗加速器的一部分

, a non-profit biotech focused on completing development and enabling commercial access to stalled rare disease treatments.

,一家非营利性生物技术公司,专注于完成停滞的罕见病疗法的开发并推动其商业化可及性。

In 2025, AGC Biologics

2025年,AGC Biologics

partnered with public benefit corporation, Rarity PBC

与公益公司 Rarity PBC 合作

, to provide end-to-end manufacturing services for Rarity’s gene therapy for ADA-SCID, an immunodeficiency disorder also known as “Bubble Baby Disease.”

,为Rarity公司针对ADA-SCID(一种也被称为“泡泡宝宝病”的免疫缺陷疾病)的基因疗法提供端到端的制造服务。

When WASKYRA was approved in December 2025, Fondazione Telethon became the first non-profit organization to receive FDA approval of a gene therapy, with

2025年12月,WASKYRA获批后,Telethon基金会成为首家获得美国食品药品监督管理局(FDA)基因疗法批准的非营利组织,

AGC Biologics as its chosen manufacturer

AGC Biologics 作为其选定的制造商

.

。

AGC Biologics has produced multiple FDA-approved therapies already in commercial supply, with additional programs currently under review. This track record makes AGC Biologics an ideal partner for a broad range of organizations, from public benefit corporations to non-profits and institutions funded by public initiatives..

AGC Biologics 已生产多种获美国食品药品监督管理局(FDA)批准并已实现商业化供应的疗法,另有更多项目正在审评中。这一业绩记录使 AGC Biologics 成为各类组织的理想合作伙伴,涵盖从公益公司到由公共倡议资助的非营利组织和机构。

What experience does AGC Biologics have in mRNA development and manufacturing?

AGC Biologics在mRNA开发和生产方面有哪些经验?

In 2023, AGC Biologics established its mRNA platform services in Heidelberg, Germany, where it already had a longstanding commercial plasmid DNA operation serving multiple customers. This services expansion also leveraged four decades of microbial manufacturing in addition to pDNA to develop its mRNA production capabilities..

2023年,AGC Biologics在德国海德堡建立了其mRNA平台服务部门。该公司此前已在当地拥有长期运营的质粒DNA商业化生产设施,服务于多家客户。此次服务扩展还依托其在微生物制造领域四十年的经验积累,除质粒DNA外,进一步开发了其mRNA生产能力。

Which AGC Biologics sites have mRNA services?

哪些AGC Biologics的站点提供mRNA服务?

AGC Biologics offers mRNA development and manufacturing services in Europe and Asia at its Heidelberg mRNA Center of Excellence in Germany and Yokohama site in Japan.

AGC Biologics 通过其位于德国的海德堡 mRNA 卓越中心和位于日本的横滨基地,在欧洲和亚洲提供 mRNA 开发和生产服务。

About Child's Cure Genetic Research

关于儿童治愈基因研究

Child's Cure Genetic Research is a parents-founded organization dedicated to developing innovative, precision treatment opportunities for rare genetic disorders in children. Driven by the urgent need to find cures, the organization envisions a future where every child has access to transformative treatments that offer hope for a better tomorrow.

儿童治愈基因研究是一家由父母创立的组织,致力于开发针对儿童罕见遗传疾病的创新精准治疗方案。在寻找治愈方法的迫切需求驱动下,该组织展望一个每个孩子都能获得变革性治疗、为更美好的明天带来希望的未来。

Through cutting-edge research and strategic collaborations, Child's Cure is committed to reshaping the future of pediatric rare disease care. Through cutting-edge research, Child's Cure is committed to reshaping the future of pediatric rare disease care—and actively welcomes strategic collaborations across other pediatric genetic conditions..

通过前沿研究和战略合作,Child's Cure 致力于重塑儿童罕见病护理的未来。凭借前沿研究,Child's Cure 致力于重塑儿童罕见病护理的未来,并积极欢迎就其他儿童遗传性疾病开展战略合作。

About AGC Biologics

关于AGC Biologics

AGC Biologics is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with a strong commitment to delivering the highest standard of service as we work side-by-side with our clients and partners, to provide friendly and expert services. We provide world-class development and manufacturing of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), messenger RNA (mRNA), viral vectors, and genetically engineered cells.

AGC Biologics 是一家全球领先的生物制药合同研发与生产组织(CDMO),我们致力于与客户及合作伙伴携手并肩,提供友好且专业的服务,始终恪守最高服务标准。我们提供世界级的哺乳动物和微生物源治疗性蛋白、质粒DNA(pDNA)、信使RNA(mRNA)、病毒载体以及基因工程细胞的开发与生产服务。

Our global network spans the U.S., Europe, and Asia, with locations in Seattle, Washington; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba and Yokohama, Japan. AGC Biologics is a part of AGC Inc.’s Life Science Business. The Life Science Business runs eight facilities focused on biopharmaceuticals, advanced therapies, small molecule active pharmaceutical ingredients, and agrochemicals.

我们的全球网络遍布美国、欧洲和亚洲,在华盛顿州西雅图、丹麦哥本哈根、德国海德堡、意大利米兰以及日本千叶和横滨设有分支机构。AGC Biologics 是 AGC 株式会社生命科学业务的一部分。该生命科学业务运营着八家设施,专注于生物制药、先进疗法、小分子活性药物成分以及农用化学品。

To learn more, visit .

欲了解更多信息,请访问。

www.agcbio.com

www.agcbio.com

.

。

Photos accompanying this announcement are available at:

随本公告发布的照片可在以下网址获取:

https://www.globenewswire.com/NewsRoom/AttachmentNg/81f0193f-0c10-4233-b072-ca4cc13654bb

https://www.globenewswire.com/NewsRoom/AttachmentNg/81f0193f-0c10-4233-b072-ca4cc13654bb

https://www.globenewswire.com/NewsRoom/AttachmentNg/2fb9fb62-bb73-40c7-a305-09b857937127

https://www.globenewswire.com/NewsRoom/AttachmentNg/2fb9fb62-bb73-40c7-a305-09b857937127